FREISING-WEIHENSTEPHAN, Germany, June 7, 2010 Pieris AGannounced today that Laurent Audoly, Ph.D., has joined the company as ChiefScientific Officer, effective immediately. Dr. Audoly, most recentlyBiologics Research Site Lead at Merck & Co. Inc., brings both pharma andbiotech experience, with extensive expertise in therapeutic protein drugdevelopment.
"Laurent has an impressive track record of leading teams and movingdiscovery programs successfully from target identification into and throughthe clinic. In particular, his pharmacology expertise and drug developmentskills are the precise ingredients we need to maximize the value of ourgrowing therapeutic pipeline," commented Stephen Yoder, CEO of Pieris. "Asthe company builds and expands its internal and partnered Anticalin pipeline,Laurent's contribution will be significant."
"As a keen proponent of targeted therapeutic technologies, I am excitedto join Pieris at a stage where the Anticalin approach is beginning todemonstrate its great therapeutic potential," added Dr. Audoly. "My goal isto combine my experience from big pharma and biotech with the capabilitiespresent at Pieris to bring the full spectrum of R&D operations to the nextlevel."
Over the course of his career, Dr. Audoly has held research andmanagerial positions of increasing responsibility, first as Senior ResearchScientist, Department of Inflammation, at Pfizer Inc. and then as SeniorResearch Fellow, Department of Pharmacology, at Merck & Co. Inc. He thenjoined MedImmune Inc. as Director R&D Inflammation and most recently held theposition at Merck and Co. Inc. as Biologics Research Site Lead. He holds adegree in Chemistry from the University of South Florida and a Ph.D. inPharmacology from Vanderbilt University. Following his studies, he completedpost-doctoral research at Duke University and the University of NorthCarolina.
Pieris AG is an independent biotechnology company advancing itsproprietary Anticalin(R) technology to create safer, more efficacious andmore convenient protein therapeutics. Exclusive to Pieris, Anticalin-baseddrugs promise to address high-unmet medical needs and expand the therapeuticpotential of current targeted approaches. Pieris' pipeline ranges from itslead program (anti-VEGF, oncology), which will enter the clinic in the firsthalf of 2010, to multiple Anticalins in preclinical development. Pieris willcommercialize Anticalin therapeutics through strategic partnerships,involving both its proprietary pipeline and its de novo drug discoverycapabilities. Its most recent partnership is with Allergan, Inc. (NYSE: AGN),focusing on novel treatments for eye diseases. Privately held, Pieris hasbeen funded by premier biotechnology-focused venture capital, including leadinvestors OrbiMed Advisors and Global Life Science Ventures.
For more information, please contact: Pieris AG, Stephen Yoder, CEO, orDr. Laurent Audoly, CSO, +49(0)8161-1411-400, firstname.lastname@example.org
SOURCE Pieris AG